Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: IMCR

Immunocore Holdings plc

Healthcare | Biotechnology

No licensed closing price on file for IMCR. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

EPS (TTM)$-0.38

Immunocore Holdings plc (NASDAQ: IMCR) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:35 UTC.

What Immunocore Holdings plc does

The company faces significant challenges in securing and maintaining patent protection for its technologies and product candidates. Patent applications may not result in issued patents, and even issued patents can be challenged, narrowed, or invalidated by competitors or third parties through various legal proceedings. The company enters into confidentiality agreements with employees and collaborators to protect proprietary information, but these parties may breach such agreements before patent applications are filed.

Summarized from Immunocore Holdings plc’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.

Key facts

Valuation
EPS (TTM)$-0.38

Revenue, margins & earnings

FY2021: net loss $180M on revenue $36M$36MFY2021FY2022: net loss $53M on revenue $174M$174MFY2022FY2023: net loss $55M on revenue $249M$249MFY2023FY2024: net loss $51M on revenue $310M$310MFY2024FY2025: net loss $36M on revenue $400M$400MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity
Source: SEC EDGAR · Filed 2026-05-28
Most recent filed transactions — May 2026:
  • 2026-05-28DirectorShare Option (Right to Buy)Award27,492—
  • 2026-05-28DirectorShare Option (Right to Buy)Award27,492—
  • 2026-05-28DirectorShare Option (Right to Buy)Award27,492—
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Immunocore Holdings plc do?

The company faces significant challenges in securing and maintaining patent protection for its technologies and product candidates.

When did IMCR last file with the SEC?

Immunocore Holdings plc's most recent SEC filing on record is a 8-K filed 2026-05-27. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-20 09:35 UTC. This page is also available as JSON at /api/data?ticker=IMCR and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for IMCR and 5,000+ tickers.

Create a free account — keep IMCR
For your agent
GET /api/data?ticker=IMCR

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt